RxDoctor Payments Data

Roy Gondo, MD

Family Medicine · Yakima, WANPI 1669476131

Payments from drug & device makers

$10,420in general payments, 2019–2025

Across 423 payments — averaging $24.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$1K
  • Boehringer Ingelheim$1K
  • Pfizer$808
  • Bayer$734
  • Novo Nordisk$603
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$10,397100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,420 in reported general payments places this provider in the 95th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$217,307
Medicare patients
409
Services billed
2,854

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide43$45,036
JardianceEmpagliflozin35$44,025
FarxigaDapagliflozin Propanediol44$36,199
EliquisApixaban28$29,782
OzempicSemaglutide25$28,828
TrulicityDulaglutide23$23,076
Tresiba Flextouch U-200Insulin Degludec17$23,006
Spiriva RespimatTiotropium Bromide14$7,328
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,439
Rosuvastatin Calcium122$3,829
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen96$2,789
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen60$1,889
Candesartan Cilexetil20$1,741
Levothyroxine Sodium110$1,227
Metoprolol Succinate96$1,095

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$119$68,11166 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat$1,048$56,79160 claims
AstraZenecaFarxiga$2,002$36,19944 claims
PfizerEliquis$808$29,78228 claims
Novo NordiskOzempic$603$28,82825 claims
AbbVieSynthroid$1,188$65016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Yakima

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →